Please try another search
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company. The Company’s lead product, TPOXX (oral TPOXX), is an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The Company does not have a manufacturing infrastructure and does not intend to develop one for the manufacture of TPOXX. It uses contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company’s CMOs apply methods and controls in facilities, which are uses for manufacturing, processing, packaging, testing, analyzing and holding pharmaceuticals, which conform to current good manufacturing practices (cGMP), the standard set by the FDA for manufacture and storage of pharmaceuticals intended for human use. For the manufacture of oral TPOXX, the Company uses the four CMOs, namely W.R. Grace and Company; Powdersize, LLC; Catalent Pharma Solutions LLC, and Packaging Coordinators, LLC.
Name | Age | Since | Title |
---|---|---|---|
Harold Ford | - | 2022 | Independent Director |
Joseph W. Marshall | 71 | 2009 | Independent Director |
Jay K. Varma | 52 | 2022 | Executive VP, Chief Medical Officer & Director |
Holly L. Phillips | 53 | 2021 | Independent Director |
Diem Nguyen | 51 | 2024 | CEO & Director |
Gary J. Nabel | 70 | 2021 | Independent Director |
Harold Eugene Ford | 54 | 2022 | Independent Director |
Evan Knisely | 49 | - | Director |
Jaymie A. Durnan | 70 | 2020 | Independent Director |
Julian Nemirovsky | - | 2020 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review